ReviewOncogene2007
Novel antibodies as anticancer agents.
Review in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6.BMC urology · 2024Article
- Article
- Monoclonal Antibodies as Neurological Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Saponin Facilitates Anti-Robo1 Immunotoxin Cytotoxic Effects on Maxillary Sinus Squamous Cell Carcinoma.Journal of oncology · 2020Article
- Article
- Nanotechnology in retinal drug delivery.International journal of ophthalmology · 2018Review
- Naïve Human Antibody Libraries for Infectious Diseases.Advances in experimental medicine and biology · 2017Review
- Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Frontiers in immunology · 2017Article
- Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies.Journal of toxicologic pathology · 2015Review
- A tool kit for rapid cloning and expression of recombinant antibodies.Scientific reports · 2014Article
- Monocytes and macrophages in cancer: development and functions.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013Article
- Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.Cancer immunology, immunotherapy : CII · 2012Article
- Novel antibody-based proteins for cancer immunotherapy.Cancers · 2011Article
- Anti-GD2 antibody therapy for GD2-expressing tumors.Current cancer drug targets · 2010Review
- Immunomodulation in the treatment of haematological malignancies.Clinical and experimental medicine · 2009Review
- Immune therapies for neuroblastoma.Cancer biology & therapy · 2009Review
- Affinity and avidity in antibody-based tumor targeting.Cancer biotherapy & radiopharmaceuticals · 2009Review
- The internally truncated LRP5 receptor presents a therapeutic target in breast cancer.PloS one · 2009Article
- Antibody fragment expression and purification.Methods in molecular biology (Clifton, N.J.) · 2009Article
- Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria.Cancer science · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.
Indexed as
Identifiers
17530025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.